Results 261 to 270 of about 4,554,323 (351)

Additive‐Assisted Modification of PDMS Nanocomposites: Rheology, Reinforcement Mechanisms, and Multifunctional Performance [PDF]

Swaroop Kumar Mandal, Rahul Kumar, Deepak Kumar, Asisha Ranjan Pradhan   +3 more
openalex   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Beyond m⁶A: The Expanding Landscape of mRNA Modifications in Renal Cell Carcinoma. [PDF]

Biomedicines
Hou Z, Tan D, Xiong Z, Miao D.
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Palmitoylation reprograms the intestinal mucosal barrier microenvironment: potential mechanisms and promising therapeutic targets. [PDF]

Front Pharmacol
Chen Y, Xiao J, Liu H, Wang Z.
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Exploring the role of RNA modifications in tumor metastasis and therapy resistance: molecular mechanisms and clinical implications

Maoyun Liu, Fengsheng Dai, Sheng Wang, Yi Wang, Cheng Zhang, Jiale Lu, 薛玉芹, Ai Shen, Dewei Li, Hui Li   +9 more
openalex   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

m6A-Targeted Cancer Therapy: Molecular Targets, Inhibitors, and Nanodelivery Strategies. [PDF]

Int J Nanomedicine
Li C, Guo Y, Jiang W, Xie W, Yao Y.
europepmc   +1 more source

Synergistic modification mechanism and pavement performance of waste LDPE/SBS composite modified asphalt mixture via dry process

Hongfu Liu, Junhong Jiang, Xiaoxue Li, Dongzhao Jin   +3 more
openalex   +1 more source